key: cord-0738694-opbeqa9u
authors: Gambichler, Thilo; Abu Rached, Nessr; Scholl, Lisa; Behle, Bertold; Mansour, Rita; Nick, Manuel; Susok, Laura
title: Reproducible leukocytoclastic vasculitis following severe acute respiratory syndrome coronavirus 2 vaccination
date: 2022-02-09
journal: J Dermatol
DOI: 10.1111/1346-8138.16282
sha: a2a3c4eb307d10093d576853e653ba16f1d3b559
doc_id: 738694
cord_uid: opbeqa9u

nan

Dear Editor, There exists increasing real-world evidence on adverse events associated with the use of the new coronavirus disease 2019 vaccines. Similar to the natural COVID-19 infection, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines appear to have also the potential to induce a broad spectrum of cutaneous adverse events. 1 We report a 47-year-old male who noticed aggregated reddish spots on his ankles occurring approximately 3 days after his first Comirnaty ® vaccination. During the following next 2 weeks, the skin lesions completely resolved without any treatment. In the literature, we identified six patients (three males, three females) who developed LCV after the COVID-19 vaccination. [1] [2] [3] [4] [5] In five cases, the mRNA-based vaccine Comirnaty was used, 1, 2, 4, 5 in one case an inactivated vaccine. 3 In most cases, characteristic symmetrical purpuric palpable papules were observed a few days after the first shot. In contrast, Akinosoglou et al. 4 

Cutaneous findings following COVID-19 vaccination: Review of world literature and own experience

Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination

New-onset leukocytoclastic vasculitis after COVID-19 vaccine

Covid-19 vaccine and autoimmunity: awakening the sleeping dragon

Leukocytoclastic vasculitis flare following the COVID-19 vaccine